Codexis has advanced enzymatic RNA manufacturing with precise stereochemical control and full-length siRNA synthesis capability, while reducing environmental impact by over 50% through aqueous processing and minimal organic solvent use. This development accelerates the scalability and sustainability of RNA therapeutics, a critical class of drugs targeting aging-related diseases and tissue regeneration.
Key Points
- Enzymatic synthesis now controls phosphorothioate stereochemistry in full-length siRNA
- Platform eliminates chemical starter oligonucleotides; enables fully enzymatic fragment ligation
- Manufacturing reduces global warming potential by 50% while improving scalability
Longevity Analysis
RNA therapeutics represent a precision intervention pathway for modulating cellular function and regenerative capacity across multiple tissues and organs. Manufacturing efficiency and purity directly determine therapeutic efficacy and cost accessibility—both essential for translation into clinical practice. The shift toward enzymatic synthesis reduces chemical byproducts that would otherwise accumulate in the body and environment, lowering the interference load on detoxification pathways while improving the probability that these drugs reach efficacy thresholds in human studies. As RNA therapeutics mature, manufacturing at scale with minimal chemical contamination becomes a foundational requirement for their integration into longevity-focused medical practice.
Original published by Longevity.Technology.